Niagen Bioscience (NAGE) Fireside chat summary

Introduction and agenda

• Discussion focused on the strategic expansion into pharmaceutical development, particularly the NB4168 drug program targeting accelerated aging and rare genetic diseases.

• Audience Q&A was included, with questions submitted live and in advance.

Background and experience of the speaker

• The team includes leading NAD researchers, such as Vil Bohr and Dr. Charles Brenner, with extensive experience in orphan diseases and anti-aging research.

• Additional world-class scientific advisors are being added to strengthen expertise.

Current industry trends

• Growing awareness and demand for NAD-related products, with steady growth in core supplement and ingredient businesses.

• Expansion into telehealth and topical NAD products, alongside pharmaceutical development.